Zydus Cadila’s Covid Wax Will Be Administered To Adults Only
The Health Ministry has given permission to start the preparatory work for inclusion of the indigenously developed, needle-free jab in the National COVID Vaccination Campaign and it may be introduced in the program any time soon.
The ministry has already placed a purchase order for one crore doses of the vaccine to the Ahmedabad-based firm.
An official source said, “ZyCov-D, which has been approved by India’s drug regulator for people aged 12 years and above, will now be given to adults only as part of the National COVID Vaccination Campaign.”
Union Health Minister Mansukh Mandaviya on Thursday said that the government does not want to rush to vaccinate children against Kovid and any decision in this regard will be taken on the basis of expert opinion.
He said that children are not being vaccinated against COVID-19 on a large scale anywhere in the world, although in some countries it has been started in a limited manner.
“About immunization of children, we will take a decision based on expert opinion. We have decided to think and evaluate before proceeding with immunization of children as they are the future of our country and we have to take this matter carefully. Need to walk,” Mandaviya had said.
Meanwhile, a comprehensive program for pediatric immunization, which includes developing a priority list of comorbidities, is being worked out by the National Technical Advisory Group on Immunization (NTAGI).
ZyCov-D is the first COVID vaccine approved by India’s drug regulator for immunization of people aged 12 years and above.
Official sources said as far as the emergency use approval by the Drug Controller General of India (DCGI) for Bharat Biotech’s Covaxin aged two to 18 years is concerned, it is subject to expert opinion and evaluation.
To give ZyCov-D to adults, a brief training will be provided to frontline workers and vaccinators on how to use the needle-free applicator in real field settings.
At present, every citizen above the age of 18 years is eligible for COVID vaccination.
Drug firm Zydus Cadila on November 8 said it has received an order to supply one crore doses of its COVID vaccine, ZyCoV-D, to the Indian government at Rs 265 per dose.
“Zydus Cadila has received an order to supply 10 million doses of ZyCoV-D, the world’s first plasmid DNA vaccine, to the Government of India at Rs 265 per dose and the needle-free applicator is being offered at Rs 93 per dose, Which does not include GST,” the pharma firm said in a regulatory filing.
The vaccine will be administered using a needle-free applicator, unlike conventional syringes. The applicant is called “Pharmajet”.
Pharmajet is a needle-free applicator to ensure painless intradermal vaccine delivery, leading to a significant reduction in any major side effects.
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, indigenously developed by the company against COVID-19, Zydus Cadila said.
Three doses of ZyCoV-D are to be given at an interval of 28 days. The vaccine was given Emergency Use Authorization (EUA) by the Indian drug regulator on 20 August.
(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is generated automatically from a syndicated feed.)
</div><div style="background: #fee8dd; padding: 12px; border: dashed 1px black; margin-bottom: 20px;">
Business Standard has always worked hard to provide updated information and commentary on events that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only reinforced our resolve and commitment to these ideals. Even during these difficult times arising out of COVID-19, we are committed to keeping you informed and updated with relevant news, authoritative views and sharp comments on relevant relevant issues.
However, we have a request.
As we grapple with the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. Subscribing to more of our online content can only help us achieve our goals of providing you with better and more relevant content. We believe in independent, unbiased and credible journalism. Your support through more subscriptions can help us practice the journalism we’re committed to.
support quality journalism and Subscribe to Business Standard,
this is an unedited and auto-generated supporting article of the syndicated news feed are actualy credit for owners of origin centers. intended only to inform and update you about Sakari naukri , result , UPSC , Exam Jobs etc. for Provides real or authentic news. also Original content may not have been modified or edited by Rojgar samachar team members.